<DOC>
	<DOCNO>NCT00494897</DOCNO>
	<brief_summary>The objective current protocol try improve result chemotherapy treatment patient ALL wich indicated peripheral stem cell transplant first remission , intensive consolidation follow re-inductions .</brief_summary>
	<brief_title>PETHEMA LAL-RI/96 : Treatment Patients With Standard Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Induction therapy : Patients standard risk receive vincristine ( 1,5 mg/m2 ) IV day 1 , 8 , 15 22 ; daunorubicin ( 30 mg/m2 ) IV day 1 , 8 , 15 22 ; oral IV prednisone 60 mg/m2/day , day 1 27 30 mg/m2/day , day 28 35 ; asparaginase 10.000 UI/m2 IM IV , day 10 12 , 17 19 24 26 ; cyclophosphamide ( 500 mg/m2 ) IV day 1 , 2 29 ; methotrexate , cytosine arabinoside hydrocortisone , day 1 22 . Patients older 55 year treat asparaginase cyclophosphamide . Consolidation therapy ( 1 ) : Standard risk : Mercaptopurine 50 mg/m2 , PO , day 1 7 , 28-35 56-63 ; methotrexate ( 3g/m2 ) IV/24 hour , day 1 , 28 56 ; VM-26 ( 150 mg/m2 ) /12 hour , IV , day 14 42 ; ARA-C ( 500 mg/m2 ) /12 hour , IV day 14-15 42-43 ; intrathecally treatment , day 1 , 28 56 . Patients 50 year : Mercaptopurine ( 50 mg/m2 ) , PO , day 1 7 , 28-35 56-63 ; methotrexate ( 1,5 g/m2 ) IV/24 hour , day 1 , 28 56 ; VM-26 ( 150 mg/m2 ) /12 hour , IV day 14 42 ; ARA-C ( 500 mg/m2 ) /12 hour , IV day 14-15 42-43 ; intrathecally treatment , day 1 , 28 56 . Consolidation therapy ( 2 ) /Reinduction : one cycle similar induction . It start one week last dose mercaptopurine.Dexamethasone 10 mg/m2/day , PO IV , day 1-14 5 mg/m2/day , PO IV day 15-21 ; VCR : 1,5 mg/m2 IV , day 1 , 8 15 ; Daunorubicin 30 mg/m2 IV , day 1 , 2 , 8 9 ; cyclophosphamide 600 mg/m2/day IV , day 1 15 ; Asparaginase : 10.000 UI/m2 IM IV , day 1-3 15-17 ; intrathecally treatment day 1 15 Maintenance therapy 1 : administration continuous chemotherapy ( mercaptopurine methotrexate ) reinductions one year diagnosis . - Continuous chemotherapy : - MP 50 mg/m2/day PO - MTX 20 mg/m2/week IM - Reinductions - VCR : 1,5 mg/m2 IV , day 1 . - PDN : 60 mg/m2/day , IV PO day 1 7 - L-ASA : 20.000 UI/m2 , IM IV day 1 . - Intrathecally day 1 Seven cycle , week 25 , 29 , 33 , 37 , 41 , 45 49 . Maintenance therapy 2 : administration continuous chemotherapy ( mercaptopurine methotrexate ) second year diagnosis ( week 53 104 ) . - MP 50 mg/m2/day , PO - MTX 20 mg/m2/week , IM .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Adults ( 15 year ) ALL standard risk prior antiblastic chemotherapy Mature BALL ( FABL3 ) cytogenetic ALL `` Burkittlike '' alteration ( [ 8 ; 14 ] , [ 2 ; 8 ] , [ 8 ; 22 ] ) Mixed form ALL Acute Leukemia differentiate Patients coronary disorder , valvular hypertensive cardiopathy Patients chronic liver disorder Chronic pulmonary disorder Renal insufficiency Neurologic disfunction ECOG 3 4 No sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>